fcn-159
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Mar 21, 2019 (NCT03932253)
Timeline
Indications
Mechanism of action
MAP3K1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C3CC3)nc(-c3cccc(NS(=O)(=O)C4CC4)c3)c21- Mol. weight
- 665.46 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068059 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07004075 | Phase 3 | Jun 30, 2025 | Fosun |
| NCT07024394 | Phase 1/Phase 2 (Phase 2) | Jun 12, 2025 | Fosun |
| NCT06913725 | Phase 2 | Feb 24, 2025 | Capital Medical University |
| NCT06553365 | Phase 2 | Aug 15, 2024 | Chinese Academy of Medical Sciences |
| NCT05997602 | Phase 2 | Sep 28, 2023 | Fosun |
| NCT04954001 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2021 | Fosun |
| NCT03932253 | Phase 1 | Mar 21, 2019 | Fosun |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fosun | For profit | 5 | 5 | 3 | 2019 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1